UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.395

Sortiert nach

Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon‐like peptide‐1 receptor agonists: A systematic analysis of published clinical trials

Diabetes, obesity & metabolism, 2017-03, Vol.19 (3), p.336-347

2017

Link zum Volltext

Verfügbarkeit prüfen

The MDM2-p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation Study

Cancer discovery, 2023-08, Vol.13 (8), p.1802

2023

Link zum Volltext

Verfügbarkeit prüfen

Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes

Diabetes, obesity & metabolism, 2018-02, Vol.20 (2), p.378-388

2018

Link zum Volltext

Verfügbarkeit prüfen

Gastrointestinal adverse events and weight reduction in people with type 2 diabetes treated with tirzepatide in the SURPASS clinical trials

Diabetes, obesity & metabolism, 2024-02, Vol.26 (2), p.473-481

2024

Link zum Volltext

Verfügbarkeit prüfen

Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials

Diabetes, obesity & metabolism, 2018-09, Vol.20 (9), p.2210-2219

2018

Link zum Volltext

Verfügbarkeit prüfen

Comparison of Remimazolam and Propofol on Postoperative Delirium in Elderly Patients Undergoing Radical Resection of Colon Cancer: A Single-Center Prospective Randomized Controlled Study

Medical science monitor, 2024-04, Vol.30, p.e943784-e943784

2024

Link zum Volltext

Verfügbarkeit prüfen

Fire dragon cupping in prevention and treatment of chemotherapy-induced nausea and vomiting in breast cancer: a randomized controlled trial

Zhōngguó zhēnjiǔ, 2024-05, Vol.44 (5), p.526

2024

Link zum Volltext

Verfügbarkeit prüfen

Upper and/or lower gastrointestinal adverse events with glucagon‐like peptide‐1 receptor agonists: Incidence and consequences

Diabetes, obesity & metabolism, 2017-05, Vol.19 (5), p.672-681

2017

Link zum Volltext

Verfügbarkeit prüfen

Effect of once‐weekly dulaglutide on glycated haemoglobin (HbA1c) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c

Diabetes, obesity & metabolism, 2018-02, Vol.20 (2), p.409-418

2018

Link zum Volltext

Verfügbarkeit prüfen

Aldehyde dehydrogenase 2 rs671 genetic polymorphisms are associated with chemotherapy-induced nausea and vomiting

Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2023-06, Vol.43 (6), p.1017

2023

Link zum Volltext

Verfügbarkeit prüfen

Nanoparticle albumin-bound paclitaxel as neoadjuvant chemotherapy of breast cancer: a systematic review and meta-analysis

Oncotarget, 2017-03, Vol.8 (10), p.17360-17372

2017

Link zum Volltext

Verfügbarkeit prüfen

The latest consensus on antiemetics

Current opinion in oncology, 2018-07, Vol.30 (4), p.233-239

Herrstedt, Jørn

2018

Link zum Volltext

Verfügbarkeit prüfen

Dapagliflozin once‐daily and exenatide once‐weekly dual therapy: A 24‐week randomized, placebo‐controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetes

Diabetes, obesity & metabolism, 2017-01, Vol.19 (1), p.49-60

2017

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of liraglutide versus sitagliptin, both in combination with metformin, in Chinese patients with type 2 diabetes: a 26-week, open-label, randomized, active comparator clinical trial

Diabetes, obesity & metabolism, 2016-08, Vol.18 (8), p.803-811

2016

Link zum Volltext

Verfügbarkeit prüfen

Gastrointestinal safety across the albiglutide development programme

Diabetes, obesity & metabolism, 2016-09, Vol.18 (9), p.930-935

2016

Link zum Volltext

Verfügbarkeit prüfen

Targeting nerve growth factor, a new option for treatment of osteoarthritis: a network meta-analysis of comparative efficacy and safety with traditional drugs

Aging (Albany, NY.), 2021-01, Vol.13 (1), p.1051-1070

2021

Link zum Volltext

Verfügbarkeit prüfen

Cost-effectiveness of newer regimens for the prophylaxis of chemotherapy-induced nausea and vomiting: review of the literature and real-world data

Current opinion in oncology, 2020-07, Vol.32 (4), p.269

2020

Link zum Volltext

Verfügbarkeit prüfen

Similar efficacy and safety of once-weekly dulaglutide in patients with type 2 diabetes aged ≥65 and <65 years

Diabetes, obesity & metabolism, 2016-08, Vol.18 (8), p.820-828

2016

Link zum Volltext

Verfügbarkeit prüfen

Controlled Release of Oxycodone as an Opioid Titration for Cancer Pain Relief: A Retrospective Study

Medical science monitor, 2020-03, Vol.26, p.e920598-e920598-7

2020

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes (LIRA-SWITCH): a randomized, double-blind, double-dummy, active-controlled 26-week trial

Diabetes, obesity & metabolism, 2016-12, Vol.18 (12), p.1191-1198

2016

Link zum Volltext

Verfügbarkeit prüfen

A vitamin B12 conjugate of exendin‐4 improves glucose tolerance without associated nausea or hypophagia in rodents

Diabetes, obesity & metabolism, 2018-05, Vol.20 (5), p.1223-1234

2018

Link zum Volltext

Verfügbarkeit prüfen

The incidence of nausea in the absence of vomiting in patients receiving intravenous chemotherapy

Annals of palliative medicine, 2021-03, Vol.10 (3), p.2679-2686

2021

Link zum Volltext

Verfügbarkeit prüfen

Prophylactic anti-emetic use to counter opioid adverse effects in the emergency department: Is it doing more harm than good?

Journal of the Pakistan Medical Association, 2023-05, Vol.73 (5), p.1168-1168

2023

Link zum Volltext

Verfügbarkeit prüfen

Chinese herbal medicines in the prevention and treatment of chemotherapy-induced nausea and vomiting

Current opinion in supportive & palliative care, 2018-06, Vol.12 (2), p.174

2018

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 1.395

Suche als RSS-Feed

Aktive Filter

Nur zeigenGeprüft (Peer-Review)

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Mit Volltextzugriff
(356)

Publikationsform

Sprache

15 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Humans
(1.374)
Nausea - Chemically Induced
(1.279)
Female
(866)
Male
(715)
Vomiting - Chemically Induced
(704)
Adult
(695)
Middle Aged
(646)
Life Sciences & Biomedicine
(563)
Science & Technology
(563)
Aged
(486)
Antineoplastic Agents - Adverse Effects
(256)
Adolescent
(229)
Oncology
(223)
Clinical Trials As Topic
(182)
Biological And Medical Sciences
(174)
Medical Sciences
(168)
Drug Evaluation
(160)
Neoplasms - Drug Therapy
(158)
Antiemetics - Therapeutic Use
(144)
Nausea - Prevention & Control
(142)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon‐like peptide‐1 receptor agonists: A systematic analysis of published clinical trials

The MDM2-p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation Study

Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes

Gastrointestinal adverse events and weight reduction in people with type 2 diabetes treated with tirzepatide in the SURPASS clinical trials

Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials

Comparison of Remimazolam and Propofol on Postoperative Delirium in Elderly Patients Undergoing Radical Resection of Colon Cancer: A Single-Center Prospective Randomized Controlled Study

Fire dragon cupping in prevention and treatment of chemotherapy-induced nausea and vomiting in breast cancer: a randomized controlled trial

Upper and/or lower gastrointestinal adverse events with glucagon‐like peptide‐1 receptor agonists: Incidence and consequences

Effect of once‐weekly dulaglutide on glycated haemoglobin (HbA1c) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c

Aldehyde dehydrogenase 2 rs671 genetic polymorphisms are associated with chemotherapy-induced nausea and vomiting

Nanoparticle albumin-bound paclitaxel as neoadjuvant chemotherapy of breast cancer: a systematic review and meta-analysis

The latest consensus on antiemetics

Dapagliflozin once‐daily and exenatide once‐weekly dual therapy: A 24‐week randomized, placebo‐controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetes

Efficacy and safety of liraglutide versus sitagliptin, both in combination with metformin, in Chinese patients with type 2 diabetes: a 26-week, open-label, randomized, active comparator clinical trial

Gastrointestinal safety across the albiglutide development programme

Targeting nerve growth factor, a new option for treatment of osteoarthritis: a network meta-analysis of comparative efficacy and safety with traditional drugs

Cost-effectiveness of newer regimens for the prophylaxis of chemotherapy-induced nausea and vomiting: review of the literature and real-world data

Similar efficacy and safety of once-weekly dulaglutide in patients with type 2 diabetes aged ≥65 and <65 years

Controlled Release of Oxycodone as an Opioid Titration for Cancer Pain Relief: A Retrospective Study

Efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes (LIRA-SWITCH): a randomized, double-blind, double-dummy, active-controlled 26-week trial

A vitamin B12 conjugate of exendin‐4 improves glucose tolerance without associated nausea or hypophagia in rodents

The incidence of nausea in the absence of vomiting in patients receiving intravenous chemotherapy

Prophylactic anti-emetic use to counter opioid adverse effects in the emergency department: Is it doing more harm than good?

Chinese herbal medicines in the prevention and treatment of chemotherapy-induced nausea and vomiting

XPD c.934G>A polymorphism of nucleotide excision repair pathway in outcome of head and neck squamous cell carcinoma patients treated with cisplatin chemoradiation

Aktive Filter

Suchergebnisse filtern